Prostate Cancer
Conditions
Brief summary
This prospectively designed retrospective clinical utility study will evaluate urologists' treatment recommendations before and after reviewing Decipher results for selected patient cases.
Detailed description
The clinical utility of Decipher will be evaluated at two time-points: 1. Post RP - within 6 months after surgery 2. PSA rise - defined as PSA detectable and rising on 2 or more subsequent determinations Patient cases will be retrospectively selected from at least 5 sites. Participating urologists at each site will be asked to each identify a minimum of 10 to a maximum of 50 suitable cases retrospectively. The resulting cases will then be de-identified, aggregated and evenly randomly distributed among the participating urologists via a secure on-line survey platform . All study participants (ie: urologists) will be masked to the original actual treatment decision and patient outcome. The design of this study is such that any participating urologist may or may not review a patient originating from their own clinical practice, but will not review a case they themselves identified. Patient cases will be de-identified and randomized amongst participating urologists . By the retrospective nature of this study, cases may be several years post-RP. It is not expected that that participation in this study will have any impact on actual clinical management of patients. Participants will be asked to complete two web-based electronic Case Report Questionnaires (eCRQ): 1. Pre-Decipher: will collect information on their recommended treatment decision and their decision confidence based on the de-identified clinical and pathological information provided for each patient case. 2. Post-Decipher: will collect their treatment recommendation and decision confidence for each de-identified patient case in the presence of the Decipher test results.
Interventions
Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
Sponsors
Columbia University
GenomeDx Biosciences Corp
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
Patient cases eligible for this study were treated with radical prostatectomy and have one or more adverse features present as defined by AUA and NCCN guidelines: * Pathological T3 stage of disease (i.e., ECE or SVI) * Positive surgical margins, or * Detectable PSA, defined as PSA detectable and rising on 2 or more subsequent determinations
Exclusion criteria
1. Metastatic Disease (M+) prior to surgery 2. Failure of PSA to nadir after surgery 3. Received any neo-adjuvant prostate cancer treatment before radical prostatectomy 4. Received any adjuvant chemotherapy 5. Required patient clinical data (Section 5.3) is not available for evaluation of eligibility criteria 6. Lack of documented treatment or management recommendation on file 7. Tissue specimen is inadequate for sampling and analysis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in treatment recommendation | 1.5 years | Change in treatment recommendation from pre- to post-Decipher report, defined as any change in treatment recommendation. Specifically this will be defined as (pre- to post-): RT to ADT RT to ADT & RT RT to Observation ADT to RT ADT to ADT & RT ADT to Observation ADT & RT to RT ADT & RT to ADT ADT & RT to Observation Observation to RT Observation to ADT Observation to RT & ADT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in intensity of treatment | 1.5 years | 2\. Change in treatment recommendation from pre- to post-Decipher report involving an increase or decrease in intensity defined as: • Increasing intensity: RT to ADT RT to ADT & RT ADT to ADT & RT Observation to any treatment • Decreasing intensity: Any treatment to observation ADT & RT to ADT ADT & RT to RT ADT to RT |
| Change in treatment recommendation compared to baseline | 1.5 years | Changes in treatment recommendation (as described in the Primary Endpoint, and in Secondary Endpoints 1 and 2) from original, actual, treatment recommendation and post-Decipher recommendation. |
| Specific change in treatment recommendation | 1.5 years | 1\. Change in treatment recommendation from pre- to post-Decipher report defined as any of the following: Observation to Any treatment Any treatment to Observation |
| Changes in the decision conflict scale | 1.5 years | — |
| Utility of Decipher | 1.5 years | Urologist's perception regarding the utility of the Decipher test |
| Confidence in treatment recommendation | 1.5 years | Changes in urologists expressed level of confidence in the treatment recommendation |
Countries
United States
Outcome results
None listed